Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Hormonal & Endocrine•Updated 2026-02-01•5 min read

    What Is GHRP-6? Benefits, Research & Safety

    The first clinically evaluated growth hormone-releasing peptide, notable for its potent GH release and pronounced appetite-stimulating effects.

    Share:X PostLinkedIn
    Also known as:
    Growth Hormone Releasing Peptide-6
    SKF-110679
    His-DTrp-Ala-Trp-DPhe-Lys-NH2
    DAnimal/cell evidence onlyUK: Unlicensed (UK)WADA: Prohibited in sport

    UK summary: Not a licensed UK medicine. Growth-hormone-releasing peptide with additional appetite-stimulating effect (it activates the ghrelin receptor). Prohibited at all times under WADA S2.

    Quick Facts

    Category
    Hormonal & Endocrine
    Half-Life
    Approximately 15-20 minutes
    UK Status
    Not licensed for human use. Research compound only.
    EU Status
    Not approved for therapeutic use.

    Overview

    GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that was one of the first growth hormone secretagogues developed and studied clinically. It stimulates growth hormone release from the pituitary by activating the ghrelin/growth hormone secretagogue receptor (GHS-R). GHRP-6 is notable for its potent appetite-stimulating effects, which result from its action on ghrelin receptors in the hypothalamus. Many users report intense hunger within 15-20 minutes of administration. This can be beneficial for those seeking to increase caloric intake but may be problematic for those trying to control weight. Beyond its GH-releasing properties, GHRP-6 has also demonstrated cardioprotective effects in some research models, protecting heart tissue from ischemia and promoting healing after cardiac injury. GHRP-6 is often combined with GHRH analogues like CJC-1295 or Sermorelin for synergistic effects on GH release. It remains a research compound not approved for therapeutic use.
    Evidence standards summary

    GHRP-6 — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

    Not a licensed UK medicine. Growth-hormone-releasing peptide with additional appetite-stimulating effect (it activates the ghrelin receptor). Prohibited at all times under WADA S2.

    02Human evidence grade

    DAnimal/cell evidence onlyStrength of evidence from published human trials.

    03Preclinical evidence grade

    BModerate human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Not licensed for human use. Research compound only.
    • EU: Not approved for therapeutic use.
    • Notes: GHRP-6 is not approved by any regulatory authority for therapeutic use. It is prohibited in sports by WADA. Available only as a research compound.

    05Approved medical uses

    None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

    06Unapproved / promotional claims

    • Stimulates GH safely for muscle gain and recovery.
    • Boosts appetite for hardgainers without side effects.
    • Safe for daily long-term cycling.
    • Undetectable by drug tests.

    07Common internet claims

    • Marketed in bodybuilding stacks for bulking phases.
    • Sold online as an appetite-stimulating GH secretagogue.
    • Promoted as the original GHRP and 'cheaper than HGH'.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Stimulates appetite for muscle-building cycles”DLimitedHighGhrelin-receptor activation does increase appetite acutely; this is not a licensed indication or a safe long-term strategy.
    “Boosts GH and IGF-1 like CJC-1295 but with appetite bonus”DLimitedHighShort-term GH response is documented; the 'appetite bonus' framing is marketing, not a licensed therapeutic claim.
    “Safe long-term for healthy adults”ENoHighLong-term human safety in healthy adults is not established.

    09Safety uncertainty score

    High

    Limited human safety data; meaningful uncertainty about rare or long-term effects.

    10Known adverse signals

    • Intense appetite stimulation (defining effect; may be unwanted).
    • Cortisol and prolactin elevation.
    • Water retention, joint pain, carpal tunnel symptoms.
    • Theoretical oncologic risk from sustained IGF-1 elevation.

    11Drug-interaction uncertainty

    High

    Interaction picture sparse; meaningful uncertainty when combined with other medicines.

    12Anti-doping status

    WADA: Prohibited in sportWADA strict-liability framing applies.

    13UK legal position

    UK: Unlicensed (UK)

    Not licensed for human use. Research compound only.

    Read the full UK legal guide → Peptides and athletes (UK)

    14EU legal position

    Not approved for therapeutic use.

    15What this page cannot tell you

    • Whether a UK-purchased vial contains GHRP-6 at the labelled concentration.
    • Whether the hunger response represents real physiologic ghrelin activation or a contaminant.
    • What chronic ghrelin-receptor activation does to metabolic and oncologic risk.
    • WADA detection windows — assume positive on test, prohibition is strict-liability.

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • No Phase 3 trials for any indication in healthy adults.
    • Long-term safety beyond a few months absent.
    • Combination-stack safety uncharacterised.
    • Cancer-surveillance data unavailable.

    19Safer alternatives / established care pathways

    • Endocrinologist review and formal GH-deficiency testing if clinically suspected.
    • Licensed recombinant HGH under specialist supervision where confirmed.
    • Calorie surplus, resistance training, and protein-adequate diet for body-composition goals.

    Related Safety Centre page → Athlete anti-doping risks

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is GHRP-6 a licensed UK medicine?
    • What's the WADA / UKAD position for athletes?
    • What are the theoretical risks of chronic ghrelin-receptor activation?

    Discovery & History

    GHRP-6 was developed in the 1980s through the work of Cyril Bowers and colleagues, who pioneered the discovery of growth hormone-releasing peptides. The research began with observations that certain synthetic peptides could stimulate GH release independently of the natural GHRH pathway. GHRP-6 emerged from systematic structure-activity relationship studies aimed at identifying potent GH secretagogues. It was designated as the sixth peptide in a series of related compounds, hence the name. The peptide was extensively studied in the late 1980s and 1990s, with clinical trials evaluating its potential for treating GH deficiency and other conditions. These studies confirmed its GH-releasing efficacy but also highlighted its appetite-stimulating effects. The discovery of ghrelin in 1999 and the cloning of its receptor (which turned out to be the target of GHRPs) provided important context for understanding GHRP-6's mechanism of action. GHRPs were effectively synthetic ghrelin mimetics developed before ghrelin itself was discovered. Despite extensive research, GHRP-6 has not achieved regulatory approval for therapeutic use. It remains available as a research compound.

    Mechanism of Action

    GHRP-6 works primarily through the ghrelin receptor: **GHS-R Activation** GHRP-6 binds to and activates the growth hormone secretagogue receptor (GHS-R), triggering GH release from pituitary somatotrophs. This is the same receptor that responds to endogenous ghrelin. **Potent Appetite Stimulation** GHRP-6's activation of ghrelin receptors in the hypothalamus produces significant appetite stimulation—often described as intense hunger. This is the most pronounced appetite effect among common GHRPs. **Effects on Other Hormones** GHRP-6 also modestly stimulates cortisol, prolactin, and ACTH release, similar to GHRP-2 but somewhat less pronounced. **Cardioprotective Effects** Research has demonstrated that GHRP-6 can protect heart tissue from ischemic injury through mechanisms that may be partly independent of GH release. These cardioprotective effects are an active area of research. **Synergy with GHRH** Like other GHRPs, GHRP-6 works synergistically with GHRH and GHRH analogues. The combination produces greater GH release than either alone.

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Potent stimulation of growth hormone release
    • 2
      Elevated IGF-1 levels
    • 3
      Significant appetite stimulation (beneficial for underweight individuals)
    • 4
      Potential cardioprotective effects
    • 5
      Possible improvements in body composition with proper nutrition
    • 6
      Synergistic effects with GHRH analogues

    Claim vs Evidence

    How popular claims about GHRP-6 stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Stimulates appetite for muscle-building cycles”DLimitedHighGhrelin-receptor activation does increase appetite acutely; this is not a licensed indication or a safe long-term strategy.
    “Boosts GH and IGF-1 like CJC-1295 but with appetite bonus”DLimitedHighShort-term GH response is documented; the 'appetite bonus' framing is marketing, not a licensed therapeutic claim.
    “Safe long-term for healthy adults”ENoHighLong-term human safety in healthy adults is not established.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical Dosage100-300 mcg per dose
    Frequency2-3 times daily, typically before meals
    DurationVariable; often cycled
    NotesGHRP-6 is not approved for therapeutic use. Its strong appetite stimulation should be considered—it may not be appropriate for those trying to limit food intake. Any use should be under medical supervision.

    Administration Routes

    Routes studied in research settings (educational only):

    • Subcutaneous injection (most common)
    Half-LifeStability
    Approximately 15-20 minutesLyophilised powder stable when properly stored; reconstituted solution should be refrigerated

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Intense hunger (very common)
    • Water retention
    • Injection site reactions
    • Flushing
    • Tingling or numbness
    • Transient cortisol elevation

    Rare Risks & Concerns

    • Effects on blood glucose
    • Unknown long-term effects
    • Potential issues with chronic cortisol elevation
    • Theoretical concerns with tumour growth

    Contraindications

    • Active malignancy
    • Pregnancy and breastfeeding
    • Diabetes (monitor closely)
    • Eating disorders (appetite effects)

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Not licensed for human use. Research compound only.

    🇪🇺 European Union

    Not approved for therapeutic use.

    GHRP-6 is not approved by any regulatory authority for therapeutic use. It is prohibited in sports by WADA. Available only as a research compound.

    Clinical Studies Summary

    Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

    This suggests that thyroid hormone excess interferes with GH-releasing pathways activated by these peptides. Our results also suggest that ghrelin's ability to increase glucose levels is not altered in thyrotoxicosis.

    Pituitary. 2007View on PubMed

    Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.

    These data show that GH responses to GHRP-6 are much greater than to GHRH in late adulthood. The marked increase of plasma GH levels observed after administration of GHRP-6 alone or in combination with GHRH indicates that impaired GH secretion in late adulthood is a functional and potentially reversible state.

    Clin Endocrinol (Oxf). 1995View on PubMed

    Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp.

    It is concluded that hyperglycemia significantly reduces GH response to combined administration of GHRH+GHRP-6 in normal weight patients with type 2 diabetes. It is suggested that ambient glucose levels should be taken into account during interpretation of GH response to combined administration of GHRH+GHRP-6 in patients with type 2 diabetes.

    Diabetes Res Clin Pract. 2004View on PubMed

    Water-in-oil microemulsions for effective transdermal delivery of proteins.

    The results using insulin, IGF-I and GHRP-6 given topically are particularly intriguing. Whether these results can be replicated in humans and whether the use of these drugs for potential treatment of obesity will be commercially viable will be particularly interesting.

    Expert Opin Drug Deliv. 2011View on PubMed

    Diagnosis of adult GH deficiency.

    In adults cut-off levels of GH response below which severe GHD is demonstrated must be appropriate to lean, overweight and obese subjects to avoid false positive diagnosis in obese adults and false negative diagnosis in lean GHD patients.

    Growth Horm IGF Res. 2008View on PubMed

    Diagnosis of adult GH deficiency.

    Overweight and obesity have confounding effect on the interpretation of the GH response to provocative tests. In adults cut-off levels of GH response below which severe GHD is demonstrated must be appropriate to lean, overweight and obese subjects to avoid false positive diagnosis in obese adults and false negative diagnosis in lean GHD patients.

    Pituitary. 2008View on PubMed

    Looking for GHRP-6?

    Source research-grade GHRP-6 from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about GHRP-6

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is GHRP-6 a licensed UK medicine?
    • What's the WADA / UKAD position for athletes?
    • What are the theoretical risks of chronic ghrelin-receptor activation?

    UK regulatory & safety context

    Peptides and athletes (UK)

    UK legal reference

    Athlete anti-doping risks

    Safety Centre guide

    Related Research Guides

    Peptides for Muscle Growth

    Read guide

    Peptides for Sleep Optimization

    Read guide

    Peptide Comparisons

    GHRP-2 vs GHRP-6

    Compare peptides

    Hexarelin vs Ipamorelin

    Compare peptides

    Sermorelin vs CJC-1295

    Compare peptides

    CJC-1295 vs Ipamorelin

    Compare peptides

    Combination Protocols

    CJC-1295 + GHRP-6 Stack

    View protocol

    Related Peptides

    CJC-1295

    A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.

    Learn more

    Ipamorelin

    A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.

    Learn more

    GHRP-2

    A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.

    Learn more

    Hexarelin

    A potent growth hormone-releasing peptide with notable cardioprotective properties independent of GH release.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.